Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies

Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.

    Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

    Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

      Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)

      Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

        Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe

        Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

          Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events

          Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

            Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

            Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

              VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market

              VIVUS' (VVUS) Qsymia sales lackluster due to slow uptake of the drug and a competitive market.

                Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin

                Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.

                  Medtronic Unveils Inner CircleSM Program, Boosts Diabetes Arm

                  Medtronic (MDT) focuses on initiatives to boost its diabetes business.

                    Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

                    Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.

                      Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates

                      Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.

                        BMY vs. NVO: Which Stock Is the Better Value Option?

                        BMY vs. NVO: Which Stock Is the Better Value Option?

                          Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label

                          Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.

                            LLY vs. NVO: Which Stock Is the Better Value Option?

                            LLY vs. NVO: Which Stock Is the Better Value Option?

                              LLY vs. NVO: Which Stock Is the Better Value Option?

                              LLY vs. NVO: Which Stock Is the Better Value Option?

                                Novo Nordisk (NVO) Announces Results in Diabetes Studies

                                Novo Nordisk (NVO) announces results from a number of studies being evaluated to treat diabetes.

                                  Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

                                  Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

                                    Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

                                    Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

                                      Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

                                      Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

                                        LLY vs. NVO: Which Stock Should Value Investors Buy Now?

                                        LLY vs. NVO: Which Stock Is the Better Value Option?

                                          Novo Nordisk's Oral Ozempic Positive in Diabetes Study

                                          Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.

                                            Mark Vickery headshot

                                            Top Research Reports for Walmart, AT&T & Novo Nordisk

                                            Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AT&T (T) and Novo Nordisk (NVO).

                                              Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

                                              Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

                                                Novo Nordisk Obtains Licence for Sickle Cell Disease Program

                                                Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

                                                  Novo Nordisk Poised on Strong Pipeline Amid Competition

                                                  Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.